Biogen Inc. said on November 9 the company was investigating the death of a 75-year-old patient who had taken the newly approved Alzheimer’s drug Aduhelm, adding that it was not yet known whether the death was related to the treatment.

Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.

A study by The National Institutes for Quantum Science and Technology in Japan found that a supplement with seven specific amino acids called Amino LP7 appeared to slow brain degeneration and dementia development in mice.

AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.

Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.

A late-stage trial of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach the study’s main goal, but secondary measures and biomarkers showed favorable trends, the company said on Oct. 17.

Supernus Pharmaceuticals Inc. is acquiring Adamas Pharmaceuticals Inc. for about $400 million as the Rockville, Maryland-based company is expanding its portfolio of treatments for Parkinson’s disease and reducing reliance on the drugmaker’s top-selling epilepsy medicine, Trokendi XR.

Alexion, the unit within global pharmaceutical firm AstraZeneca that focuses on finding treatments for rare diseases, is halting clinical trials for Ultomiris (ravulizumab) for adults with amyotrophic lateral sclerosis.

Novartis will launch a new phase three study to expand the use of Zolgensma – the world’s most expensive one-time therapy at $2.1 million per patient treatment – after the U.S. regulator lifted its restrictions.

Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).